Detalhe da pesquisa
1.
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?
Haematologica;
109(3): 888-894, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37646655
2.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol;
40(5): 1009-1019, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35638723
3.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol;
108(3): 178-189, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34716957
4.
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Am J Hematol;
97(12): 1607-1615, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36198076
5.
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.
Am J Hematol;
97(7): 877-884, 2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35389534
6.
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.
Int J Mol Sci;
23(20)2022 Oct 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36293315
7.
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Hematol Oncol;
39(1): 41-50, 2021 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33085797
8.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Ann Hematol;
96(12): 2071-2078, 2017 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29063955
9.
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Am J Hematol;
90(7): 647-52, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25858483
10.
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Exp Cell Res;
328(2): 444-55, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25257607
11.
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Ann Hematol;
93(1): 123-8, 2014 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23864035
12.
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Am J Hematol;
89(12): 1085-91, 2014 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25159313
13.
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy.
Cells;
13(10)2024 May 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38786075
14.
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight.
Leuk Res Rep;
21: 100399, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38078287
15.
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.
Nat Commun;
15(1): 1551, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38378709
16.
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
Cells;
13(8)2024 Apr 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38667272
17.
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.
Haematologica;
103(6): e277-e278, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29622654
18.
Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models.
Haematologica;
103(12): e602-e606, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30026343
19.
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Clin Exp Med;
23(8): 5227-5239, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37815734
20.
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.
Front Oncol;
13: 1208741, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37305577